Inovio Pharmaceuticals (INO) Stock Statistics & Valuation Metrics

Inovio Pharmaceuticals has a market cap or net worth of $78.07M. The enterprise value is $25.65M.

Inovio Pharmaceuticals has 69,091,960 shares outstanding. The number of shares has decreased by -2.65% in one year.

Inovio Pharmaceuticals’s return on equity (ROE) is -3.53 and return on invested capital (ROIC) is -259.45%.

The current PE Ratio of Inovio Pharmaceuticals is ―. Inovio Pharmaceuticals’s PEG ratio is 0.18.

In the last 12 months, Inovio Pharmaceuticals had revenue of 65.34K and earned -84.95M in profits. Earnings per share was -1.81.

In the last 12 months, operating cash flow was -88.63M and capital expenditures -285.70K, giving a free cash flow of -88.92M billion.

Inovio Pharmaceuticals pays an annual dividend of $0.069, resulting in a dividend yield of ―

Inovio Pharmaceuticals upcoming earnings date is May 12, 2026, TBA (Confirmed).

Inovio Pharmaceuticals as a current ratio of 1.40, with Debt / Equity ratio of 38.88%

In the past 12 months, Inovio Pharmaceuticals has paid 0.00 in taxes.

Inovio Pharmaceuticals EV to EBITDA ratio is -9.53, with an EV/FCF ratio of -8.78.

Inovio Pharmaceuticals has $58.51M in cash and marketable securities with $9.37M in debt, giving a net cash position of $49.14M billion.

Gross margin is -2189.03%, with operating margin of -132871.32%, and net profit margin of -130000.00%.

The average price target for Inovio Pharmaceuticals is $4.50, which is 11.43% higher than the current price. The consensus rating is Moderate Buy